MoonLake Immunotherapeutics
- Country
- 🇨🇭Switzerland
- Ownership
- Public
- Employees
- 50
- Market Cap
- $2.9B
- Website
- http://www.moonlaketx.com
- Introduction
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.
Merck Explores $3+ Billion Acquisition of Swiss Biotech MoonLake Immunotherapeutics
Merck has held acquisition talks with Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, according to Financial Times reports citing three people familiar with the matter.
MoonLake Launches Three Clinical Trials for Sonelokimab in Inflammatory Diseases
MoonLake Immunotherapeutics has initiated three new clinical trials to evaluate sonelokimab across adolescent hidradenitis suppurativa, palmoplantar pustulosis and axial spondyloarthritis.
Hidradenitis Suppurativa: Advances in Treatment and Research Highlighted in 2024
Bimekizumab gains EU approval and FDA acceptance for HS treatment based on Phase 3 BE HEARD trials, demonstrating significant improvements in skin pain.
MoonLake Immunotherapeutics Initiates Phase 3 Program for Sonelokimab in Psoriatic Arthritis
MoonLake Immunotherapeutics has commenced its Phase 3 IZAR program to evaluate sonelokimab for active psoriatic arthritis (PsA) across two clinical trials.
Spinal Cord Injury and Ankylosing Spondylitis: Advances in Clinical Trials and Therapies
Spinal Cord Injury (SCI) pipeline includes 35+ therapies from companies like Athersys and NervGen Pharma, targeting mechanisms from stem cell therapy to neuroprotection.
MoonLake Immunotherapeutics Reports Progress on Sonelokimab and Financial Results in Q3 2024
MoonLake Immunotherapeutics reported a net loss of $36.1 million for Q3 2024, driven by increased research and development expenses related to Sonelokimab (SLK).
MoonLake Immunotherapeutics Initiates Phase 3 VELA Program for Sonelokimab in Hidradenitis Suppurativa
MoonLake Immunotherapeutics has commenced its Phase 3 VELA program to evaluate sonelokimab for moderate-to-severe hidradenitis suppurativa (HS).